Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.

World journal of gastroenterology - 14 Jun 2016

Ampuero Javier, Reddy K Rajender, Romero-Gomez Manuel

Abstract excerpt

AIM: To address the therapeutic efficacy of various treatment regimens in genotype 3 selecting randomized clinical trials and prospective National Cohort Studies. METHODS: (1) PEG-INF-based therapy including sofosbuvir (SOF) + RBV for 12 wk vs SOF + RBV 24 wk; (2) SOF + RBV therapy 12 wk/16 wk vs 24 wk; and (3) the role of RBV in SOF + daclatasvir (DCV) and SOF + ledipasvir (LDV) combinations. This meta-analysis...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Carbamates

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Imidazoles

Share to Pyrrolidines

Share to Randomized Controlled Trials as Topic

Share to Sofosbuvir

Share to Sustained Virologic Response

Share to Valine

Source

Open in PubMed Open full text

Identifiers

PMID: 27298572
DOI: 10.3748/wjg.v22.i22.5285
PMCID: PMC4893476

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Hepatitis C virus genotype 3: Meta-analysis on sustained virologic response rates with currently available treatment options.PMID 27298572Read ↗

Effectiveness of current and future regimens for treating genotype 3 hepatitis C virus infection: a large-scale systematic review.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3 infection with direct-acting antiviral agents.Semantic proximity Read ↗

Interferon-free treatments in patients with hepatitis C genotype 3 infection in a tertiary hospital.Semantic proximity Read ↗

Hepatitis C Virus: Current and Evolving Treatments for Genotypes 2 and 3.Semantic proximity Read ↗

Therapy for hepatitis C genotype 3: moving forward.Semantic proximity Read ↗

Treatment of hepatitis C virus genotype 3-infection.Semantic proximity Read ↗

All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study.Semantic proximity Read ↗

Interferon-free therapies for patients with chronic hepatitis C genotype 3 infection: A systematic review.Semantic proximity Read ↗

Meta-analysis: the outcome of anti-viral therapy in HCV genotype 2 and genotype 3 infected patients with chronic hepatitis.Semantic proximity Read ↗

Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Treatment of patients with genotype 3 chronic hepatitis C--current and future therapies.Semantic proximity Read ↗

Hepatitis C Genotype 3 Infection: Pathogenesis and Treatment Horizons.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.